← All trials
NCT01900327
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2014
- Primary completion
- Feb 1, 2020
- Completion date
- Dec 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 410
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of HamburgLead sponsor
- Saarland UniversityCollaborator
- SRH Wald-Klinikum Gera GmbHCollaborator
- University of HeidelbergCollaborator
- Ruhr University BochumCollaborator
- Friedrich Schiller UniversityCollaborator
- University of RostockCollaborator
- University of RegensburgCollaborator
- Gottfried Wilhelm Leibniz Universität HannoverCollaborator
- University of TuebingenCollaborator
- Ludwig Maximilians UniversityCollaborator
- Technical University of MunichCollaborator
- University of FreiburgCollaborator
- University of HamburgOverall official - principal investigator
- Universitaetsklinikum Schleswig-HolsteinCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.